Amniotic membrane graft for long-lasting diabetic foot and venous leg ulcers
Observes EPIFIX graft safety and effects in people with diabetic foot or venous leg ulcers.
Key facts
- Who runs it
- MiMedx Group, Inc.
- Where
- Japan5 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Post-Marketing Surveillance of Dehydrated Human Amnion/Chorion Membrane (DHACM) in Non-Ischemic Chronic Wounds
- Status
- Recruiting
- People taking part
- 75 people, planned
- Started
- 4 Aug 2023
- Expected to end
- Jan 2027
- Type of study
- Interventional
- Treatments tested
- EPIFIX
- Record updated
- 1 February 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with hard-to-heal diabetic foot ulcers or venous leg ulcers. It studies the EPIFIX wound graft, made from dried human amnion/chorion membrane (layers of the birth sac).
- Sex
- All sexes can join.
- Disease stage
- Diabetic foot ulcer or venous leg ulcer that has not shrunk in area by at least 50% after 4 weeks of usual treatment.
- Earlier treatment
- At least 4 weeks of usual wound care, such as removing dead tissue, infection control, wound cleaning, blood sugar control for diabetic foot ulcers, compression for venous ulcers, and moist wound dressings.
Main reasons for not taking part
- Active or hidden infection in the wound area.
- Conditions that make problems after the procedure too risky.
- Ulcers that cannot be cleaned of dead tissue well enough, or where poor blood flow lets the wound bed die early after cleaning.
- Several ulcer areas with exposed bone and no blood flow in the wound bed.
- Allergy to the aminoglycoside antibiotics used in making the graft.
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Patients with intractable diabetic foot ulcers or venous leg ulcers that have not decreased in surface area by at least 50% after 4 weeks of conventional therapies, such as radical wound management (removal of necrotic tissue, infection control, wound cleansing, etc.), glycemic control for diabetic foot ulcers, compression therapy for venous stasis ulcers and moist therapy using wound dressing materials
Who cannot take part
- Areas of active infection or latent infection
- Patients with disorders that would cause an intolerable risk of postoperative complications
- Ulcers that, after debridement, have blood flow disorders where wound bed necrosis progresses at an early stage
- Wound surfaces with multiple ulcer surfaces and exposed bone, and no blood flow in the wound bed
- Patients with hypersensitivity to the aminoglycoside antibiotics used during manufacturing
- Ulcers that cannot be sufficiently debrided
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this survey is to observe the efficacy and safety of EPIFIX® dehydrated human amnion/chorion membrane (DHACM) for the treatment of intractable diabetic foot ulcers or venous leg ulcers.
The group in the trial
- Patients with Non-Ischemic Chronic WoundsTreatment being tested
Patients with intractable diabetic foot ulcer or venous leg ulcer that have not decreased in surface area by at least 50% after 4 weeks of conventional therapies.
Treatment: EPIFIX
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Post-Marketing Surveillance to Observe the Safety and Efficacy of Dehydrated Human Amnion/Chorion Membrane (DHACM) Wound Graft in the Management of Non-Ischemic Chronic Wounds
- Plain-language title
- Amniotic membrane graft for long-lasting diabetic foot and venous leg ulcersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 1 February 2024